BRAF and cutaneous melanoma: The BRAF mutation V600E, which correlates with a poor prognosis in skin melanoma patients [61], has been used for designing a CRISPR/Cas9 system that specifically targets the mutated BRAF gene in A375 and G361 melanoma cell lines and mediates cleavage upon stimulation with blue light.